High-dose anthracycline therapy in childhood cancer survivors was associated with significantly lower exercise capacity (84.4% of predicted VO2peak; p=0.017) and abnormal NTproBNP levels (p=0.024).
Observational (n=136)
Does anthracycline-based childhood cancer therapy affect long-term vascular structure, cardiac biomarkers, and exercise capacity compared to healthy controls?
NTproBNP and exercise capacity, but not cIMT or troponin, may serve as early markers for cardiovascular dysfunction in childhood cancer survivors.
Introduction: Childhood cancer survivors (CCS) might be at high risk of additional chronic diseases due to cardiotoxic side effects. The aim of this study was to analyze long-term side effects of cancer therapy on vascular structure/function, cardiac biomarkers and on physical activity. Methods: In total, 68 asymptomatic patients aged 16–30 years with childhood cancer (diagnosed 10.6 ± 3.9 years ago) were examined from 2015–2020. (Central) blood pressure and pulse wave velocity were registered via the oscillometric method, while carotid intima-media thickness (cIMT) was measured non-invasively by ultrasound. cIMT values of patients were compared to healthy controls (n = 68; aged 22.3 ± 3.5 years). Patients’ exercise capacity was recorded. The plasma N-terminal pro-brain natriuretic protein (NTproBNP) and troponin levels were measured as cardiac biomarkers. CCS were categorized in groups with low, moderate and high anthracyclines. Results: No differences were found in cIMT between patients and controls as well as between patients with various anthracycline dosage. Patients with high dose anthracyclines showed a significant lower performance versus patients with moderate dose anthracyclines (84.4% of predicted VO2peak; p = 0.017). A total of 11.6% of CCS had abnormal NTproBNP values which correlated with received anthracycline dosage (p = 0.024; r = 0.343). Conclusion: NTproBNP levels and exercise capacity might be early markers for cardiovascular dysfunction in CCS and should be included in a follow-up protocol, while cIMT and troponin seem not to be adequate parameters.
Reiner et al. (Wed,) conducted a observational in Childhood cancer survivors (n=136). Anthracycline therapy vs. Healthy controls and lower dose groups was evaluated on Vascular structure/function (cIMT), cardiac biomarkers (NTproBNP, troponin), and physical activity. High-dose anthracycline therapy in childhood cancer survivors was associated with significantly lower exercise capacity (84.4% of predicted VO2peak; p=0.017) and abnormal NTproBNP levels (p=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: